|1.||Keating, Aileen F: 2 articles (02/2015 - 05/2014)|
|2.||Ganesan, Shanthi: 1 article (02/2015)|
|3.||Devine, Patrick J: 1 article (05/2014)|
|4.||Madden, Jill A: 1 article (05/2014)|
|5.||Hoyer, Patricia B: 1 article (05/2014)|
|6.||Bhatia, K: 1 article (10/2006)|
|7.||Ali, M: 1 article (10/2006)|
|8.||Atif, F: 1 article (10/2006)|
|9.||Kaur, M: 1 article (10/2006)|
|10.||Raisuddin, S: 1 article (10/2006)|
06/01/1992 - "This study examined the in vivo genotoxic effects of occupational exposure to anti-cancer drug handling by relating baseline and phosphoramide mustard (PM) -induced SCE levels with duration of anti-cancer drug handling as a surrogate for anti-cancer drug exposure dose. "
07/01/1990 - "This study examined the in-vivo genotoxic effects of CP therapy by comparing baseline and phosphoramide mustard (PM)-induced SCEs in therapeutically (in-vivo) treated cancer patients with SCE levels in newly diagnosed, but not treated patients. "
05/15/2014 - "CPA requires bioactivation to phosphoramide mustard (PM) to elicit its therapeutic effects however; in addition to being the tumor-targeting metabolite, PM is also ovotoxic. "
12/01/1994 - "Thus increased levels of GST A1-1 in tumor cells can contribute to an enhanced detoxification of phosphoramide mustard and hence to the development of drug resistance. "
06/01/1992 - "Baseline and phosphoramide mustard-induced sister-chromatid exchanges in pharmacists handling anti-cancer drugs."
01/01/1999 - "The human medulloblastoma cell line D283 Med (4-HCR), a line resistant to 4-hydroperoxycyclophosphamide (4-HC), displays enhanced repair of DNA interstrand crosslinks induced by phosphoramide mustard. "
08/01/1988 - "These results extend our previous studies demonstrating the antitumor activity of nitrogen and phosphoramide mustard-based bifunctional alkylating agents in the treatment of human medulloblastoma continuous cell lines and transplantable xenografts, and support the continued use of these agents in clinical trials."
|3.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
02/01/1991 - "These compounds were also tested for cytotoxicity against L1210 leukemia and B16 melanoma cells in vitro; the monoalkylators 4c and 4d showed no activity, 4a was weakly cytotoxic, and 4b was comparable in activity to phosphoramide mustard."
01/01/1984 - "Observations on the effects of cyclophosphamide, phosphoramide mustard and some activated oxazaphosphorines on murine L1210 leukemia."
03/01/1984 - "Murine tumor testing of the phosphoramide mustard derivatives and two intermediates indicated that two compounds possessed marginal activity against mammary carcinoma and lymphocytic leukemia."
11/01/2004 - "5. Alternative prodrugs may eventually prove superior to CB1954; a nitroaryl phosphoramide mustard prodrug activated by NTR shows a greater therapeutic index than CB1954 in a human ovarian carcinoma. "
|7.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)